Strikingly, in a vaccination setting, the addition of PD-1 blockade to OX40 agonists virtually eliminates the antitumor effect of OX40 monotherapy due to the reduced TIL infiltration and enhanced cell death of tumor-reactive CD8+ T cells (186). The gene discussed is TNFRSF4; the disease is neoplasm.